Medically assisted reproduction - MAR

Help with your plan for a baby, thanks to MAR

Because your story matters to us, we try to offer you all the help you may need to achieve your desire for a baby.

Changes resulting from the revision of the RMA (Reproductive Medicine Act)

From 1 September 2017, important changes have allowed couples to maximise their chances of becoming a parent

These changes include:

  • The number of embryos that can be developed during a treatment cycle increases from three to 12.
  • Unused embryos can be frozen with a view to later treatment for a duration of five years, renewable on request (maximum duration of 10 years).
  • Preimplantation genetic diagnosis (PGD) is authorised*.

*PGD is a procedure that is authorised in two cases: only couples carrying a severe hereditary disease (preimplantation diagnosis) and couples who cannot reproduce naturally can decide to have this examination (preimplantation genetic screening).

Your specialist MAR team

With more than 30 years' experience, the Fertility Medicine and Gynaecological Endocrinology unit at CHUV offers you personalised and understanding care, combining the most highly specialised expertise with the most advanced technologies.

Throughout yourmedically assisted reproduction journey,you are cared for and advised by doctors who specialise in reproductive medicine, biologists, psychologists, sexual and reproductive health advisers, nurses, laboratory technicians and administrative assistants.

The specialists looking after you work together and help you to make the most suitable choices. They listen and respond to your expectations and concerns.

Who are we?

At the centre of a university network

Welcomed into the heart of the CHUV hospital complex, you benefit from direct access to the complementary skills provided by other departments and covering areas such as genetics, endocrinology, oncology, haematology, psychiatry and ethics.

The CHUV Reproductive Medicine Unit is certified to the ISO standard 9001:2015, guaranteeing its high quality standards.

Quality Assurance

Specialist MAR laboratory

All the tests required to understand and treat your case of infertility, whether female or male, are performed in the Andrology and Reproductive Biology Laboratory (ARBL), which is accredited to the ISO standard 15189:2012. This accreditation confirms the excellence of the work performed by the ARBL.


Vaccination COVID-19 et PMA, quelles recommandations ?

Pour les femmes qui envisagent de démarrer un traitement de procréation médicalement assistée, nous recommandons, dans la mesure du possible, de se faire vacciner avant de recevoir une insémination ou un transfert d’embryon.

Concrètement, nous conseillons d’attendre 2 semaines après la seconde injection du vaccin avant de programmer un traitement en vue d'une insémination ou d'un transfert d’embryon.

Si la femme a déjà débuté une grossesse, cette décision devra être prise en accord avec son médecin et après avoir examiné le rapport risque-bénéfices. l’OFSP et la Société suisse de Gynécologie et d’Obstétrique s’accordent pour ne vacciner que les femmes enceintes à haut risque de complications liées au Covid, au cours du 2e ou du 3e trimestre ; ceci après un entretien d’information auprès d’un professionnel de santé et sur la base d’une prescription écrite. Il n’existe en effet pas encore de données cliniques qui garantissent totalement la sécurité de la vaccination chez les femmes enceintes.

Our media experts

Our services at a glance

 Last updated on 04/05/2021 at 08:22